[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 400", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "415 798 8589", "website": "https://www.tempesttx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen R. Brady J.D., LLM", "age": 53, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 923235, "exercisedValue": 0, "unexercisedValue": 262204}, {"maxAge": 1, "name": "Dr. Sharon  Sakai Ph.D., RAC", "title": "Head of Regulatory & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.44, "open": 3.37, "dayLow": 3.31, "dayHigh": 3.48, "regularMarketPreviousClose": 3.44, "regularMarketOpen": 3.37, "regularMarketDayLow": 3.31, "regularMarketDayHigh": 3.48, "beta": -2.827, "forwardPE": -2.27451, "volume": 287166, "regularMarketVolume": 287166, "averageVolume": 989279, "averageVolume10days": 464180, "averageDailyVolume10Day": 464180, "bid": 3.45, "ask": 3.5, "bidSize": 400, "askSize": 100, "marketCap": 77316208, "fiftyTwoWeekLow": 0.17, "fiftyTwoWeekHigh": 9.77, "fiftyDayAverage": 3.7255, "twoHundredDayAverage": 2.89227, "currency": "USD", "enterpriseValue": 58659252, "floatShares": 17774703, "sharesOutstanding": 22217300, "sharesShort": 1127331, "sharesShortPriorMonth": 766843, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0507, "heldPercentInsiders": 0.00063, "heldPercentInstitutions": 0.29237, "shortRatio": 0.64, "shortPercentOfFloat": 0.063, "impliedSharesOutstanding": 22217300, "bookValue": 1.214, "priceToBook": 2.866557, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -29491000, "trailingEps": -1.91, "forwardEps": -1.53, "lastSplitFactor": "1:15", "lastSplitDate": 1624838400, "enterpriseToEbitda": -2.038, "52WeekChange": 0.6415094, "SandP52WeekChange": 0.21080327, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TPST", "underlyingSymbol": "TPST", "shortName": "Tempest Therapeutics, Inc.", "longName": "Tempest Therapeutics, Inc.", "firstTradeDateEpochUtc": 1352730600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d54d822e-cd83-39cb-b46d-5c9b6edb9502", "messageBoardId": "finmb_552715229", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.48, "targetHighPrice": 47.0, "targetLowPrice": 8.0, "targetMeanPrice": 18.6, "targetMedianPrice": 13.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 39230000, "totalCashPerShare": 1.768, "ebitda": -28776000, "totalDebt": 20661000, "quickRatio": 4.169, "currentRatio": 4.289, "debtToEquity": 77.185, "returnOnAssets": -0.37307, "returnOnEquity": -1.31424, "freeCashflow": -17474750, "operatingCashflow": -27357000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]